Exact Sciences files for stock offering

On the heels of an FDA panel’s recent approval of Exact Sciences’ cancer-screening test Cologuard, the company has signaled that it may sell stock or debt securities in the near future. The Madison company filed with the SEC to offer $125 million in shares of common stock, though no specific date was set.